$Conference + 2 Workshops - Drug Developer USD 2597.00, Conference + 1 Workshop - Drug Developer USD 2348.00, Conference Only - Drug Developer USD 2099.00, Conference + 2 Workshops - Academic & Non-for-profit USD 2197.00, Conference + 1 Workshop - Academic & Non-for-profit USD 2048.00, Conference Only - Academic & Non-for-profit USD 1899.00, Conference + 2 Workshops - Product & Solution provider Pricing USD 3297.00, Conference + 1 Workshops - Product & Solution provider Pricing USD 2948.00, Conference Only - Product & Solution provider Pricing USD 2599.00
Lectures & Conferences
The 5th Digital DDR, ATR & PARP Inhibitors Summit is coming at a timely inflection point within this field. With Wee1 & ATR approvals on the horizon and countless novel targets currently undergoing exciting pre-clinical validation, this unique & highly anticipated meeting unites the world experts in DDR inhibition to propel this space through the barriers it faces to clinical breakthrough.
This industry-led forum once again evolves to reflect progress in the DDR therapies field with focused content on:
PARP Inhibition: Next-Gen PARPi’s, PARP Resistance & the Future of PARP Inhibitors
Developing Clinically Successful Wee1 & ATR Inhibitors for Cancer Therapy
Developing Predictive Pre-Clinical Models in DDR to Achieve Human-Specific Translation
Novel Methodologies & Imaging Technologies to Revolutionize Pathway Understanding, Compound Optimization & Clinical Translation
Establishing a Pre-Clinically Validated Novel Target: Polθ
Identifying Reliable DDR/HR Tumor Biomarkers
Exploring the Emerging Targets in the DDR Pathway: Strategy, Execution, Development and Promise
Managing Toxicity - Dose, Delivery, Scheduling, Patient Selection, & Stratification - Managing the Therapeutic Window & Treatment Regimes
Next Steps in Combination Approaches - to Heighten Drug Effect & Overcome Resistance - What is the Future of the Field?
Speakers: Andrew Wylie Senior Vice President & Head of Oncology KSQ Therapeutics, Nathalie Agar Director of Surgical Molecular Imaging, Laboratory & Department of Neurosurgery Brigham & Women’s Hospital Department of Cancer Biology Dana-Farber Cancer Institute, Timothy Yap Associate Professor, Investigational Cancer Therapeutics MD Anderson Cancer Center, Geoffrey Shapiro Professor, Medicine, Harvard Medical School, Director of Early Drug Development Center Dana-Farber Cancer Institute, Caroline Ben Chief Scientific Officer & Co- Founder LoQus23 Therapeutics, Ioannis Gounaris Senior Medical Director Cluster Lead DNA Damage Response (DDR) Inhibitors, Global Clinical Development Oncology Group II Merck KGaA, Frank Zenke Global Head DNA Damage Response Research Merck KGaA, John Pascal Professor of Biochemistry & Molecular Medicine University of Montreal, Oren Gilad Chief Executive Officer Atrin Pharmaceuticals, Debanu Das Chief Executive Officer XPose Therapeutics, Zineb Mounir Director, Biology & Translational Science IDEAYA Biosciences, Sui Xiong Cai Executive Vice President & Chief Technology Officer IMPACT Therapeutics, Mark O’Connor Chief Scientist & Senior Principal Scientist AstraZeneca, Ranjit Bindra Professor, Departments of Therapeutic Radiology & Pathology Yale School of Medicine, Peter Huang Senior Vice President Discovery Zentalis Pharmaceuticals, Elisabetta Leo Principal Scientist - Associate Director AstraZeneca, Kent Mouw Assistant Professor of Radiation Oncology Dana-Farber Cancer Institute, Nicola Curtin Experimental Therapeutics Professor Newcastle University, Helen Robinson Vice President of Biology Artios Pharma, Alan D’Andrea Director: Center for DNA Damage and Repair, Director Susan F. Smith Center for Women’s Cancers (SFSCWC) Professor Harvard Medical School Dana-Farber Cancer Institute, Kirk Tanner Chief Scientific Officer National Brain Tumor Society, Tatjana Stankovic Institute of Cancer and Genomic Sciences University of Birmingham, Katie Pawelczak VP of Research NERx Biosciences, Sotirios Sotiriou Head of Biology & Co-Founder FoRx Therapeutics, John Pollard Vice President & Global Head of Translational Medicine & Oncology Bay, Eytan Ruppin Chief - Cancer Data Science Lab National Cancer Institute, Wael Jdey Lead Scientist Onxeo, Daniel Speidel Managing Director & Co-Founder Breakpoint Therapeutics, Graeme Smith Chief Scientific Officer Artios Pharmaceuticals, Michael Zinda Chief Scientific Officer, Executive Vice President, Head of Research & Development Repare Therapeutics, Arne Nedergaard Kousholt Postdoctoral Researcher Jos Jonkers Group, Division of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute, Asli Muvaffak Associate Director - Scientific, Oncology, Synthetic Lethality & Research Unit GSK, Laure Escoubet Vice President, Discovery Biology Zentalis Pharmaceuticals, Asima Mukhopadhyay Gynaecological Oncologist & Clinician Scientist, Chittaranjan National Cancer Institute India & Newcastle University, Jennifer Molina Principal Scientist Ribon Therapeutics